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Background: Despite the large burden medication related morbidity and mortality places on 
the Australian healthcare system, there is little known about the extent of this problem in a 
women’s health (obstetric and gynaecology) setting.  
Objective: Determine the frequency and nature of medication related problems (MRPs) 
occurring in a women’s health unit (WHU) of an Australian teaching hospital. 
Methods: A prospective audit of consecutive cases of patients treated in the Women’s Health 
Unit at a tertiary level teaching hospital was undertaken by a clinical pharmacist over a five 
week period. Data collected included: patient characteristics, type of MRP (using a modified 
version of the Hepler-Strand classification system), medication involved (according to the 
World Health Organisation Anatomical Therapeutic Chemical classification system) and 
clinical significance (using a two-level severity index).  
Results: A total of 454 potential MRPs identified over the five week period among 241 
patients. A total of 39 MRPs (8.6%) identified were deemed to be of moderate/high clinical 
significance. The highest number of MRPs (221; 49%) were identified amongst women 
admitted following a caesarean delivery, with 83 of 85 women in this group experiencing at 
least one MRP. Additional factors associated with an increased likelihood of patient’s 
experiencing a MRP included increased age, length of hospital stay and number of regular 
medications taken prior to and during admission(p<0.05). 
Conclusion: The widespread nature of identified MRPs in this setting suggest various 
approaches to minimising these problems and mitigating the associated burden on the 









An Australian landmark study undertaken almost two decades ago reported that 16.6% of 
admissions to hospitals were associated with an iatrogenic adverse event, with medication-
related adverse events being large contributors to this figure.1 Such medication related 
adverse events are commonly delineated in terms of a framework proposed by Hepler and 
Strand, which defined a Medication Related Problem (MRP) as “an event or circumstance 
involving drug treatment that actually or potentially interferes with the patient experiencing 
an optimum outcome of medical care”.2 While MRP prevalence rates vary significantly 
across different populations and different studies, likely owing to differing study designs and 
the lack of a universal definition of MRPs, there remains a clear consensus from all studies 
that MRPs are not only common but also of significant concern to the healthcare system.3-5 
 
A recognised approach to counteracting MRPs and reducing their associated negative burden 
has been the expanded role of ward based clinical pharmacy services.6 Studies have 
demonstrated that increased staffing levels for clinical pharmacists and pharmacist-provided 
admission histories were associated with a statistically significant reduction in medication 
errors and subsequently patient morbidity and mortality.5, 7-9 A particularly unique challenge 
within the women’s health setting is that of medication use during pregnancy and lactation. 
Prescribing medications to women during pregnancy and lactation is often a complex 
multifactorial scenario, with the need to balance the associated benefits and risks to both the 
mother and child.10 Furthermore, the numerous physiological changes that occur during 
pregnancy can alter medication pharmacokinetics.11 In addition, obstetric patients are 
certainly not exempt from experiencing conditions that may require medication therapy, with 
chronic health conditions, obstetric related conditions and complications arising in labour and 
delivery each affecting an estimated proportion of between 30 and 40% of obstetric patients 




each year.12 Further to this, medication use appears to be almost ubiquitous amongst pregnant 
women with Australian studies reporting that up to 97% of women use at least one 
medication (non-prescription medications more commonly used than prescription 
medications) and 26.5% of women were using at least one prescribed medication during 
pregnancy.13, 14 
 
Few studies have investigated the nature and prevalence of MRPs occurring within a 
women’s health setting.15-20 Three previous studies have focused on the evaluation of self-
reporting error databases,17-19 and while these reports may be useful in highlighting examples 
of medication errors, they are unable to determine the true frequency with which they occur.  
An additional three studies have focused on evaluating medication errors associated at the 
point of medication orders (e.g. point of prescribing/dispensing)15, 16, 20, demonstrating 
variability in the extent to which errors occur, with errors ranging from 0.4/100 orders20, up 
to 4.2/100 orders16. Notably, as none of these previous studies involved the identification of 
MRPs following the completion of a detailed pharmacist-provided medication history and 
clinical evaluation, they are likely to represent an underestimate of the true number of MRPs. 
Therefore, the aim of this study was to examine the frequency and nature of MRPs occurring 
in an obstetrics and gynaecology hospital inpatient setting. 
 
Methods 
Ethics approval was obtained from the University of South Australia and the Lyell McEwin 
Hospital/Queen Elizabeth Hospital/Modbury Hospital Human Research and Ethics 
Committees. 
 




A prospective clinical audit of consecutive cases of patients treated in the Women’s Health 
Unit (WHU) at the Lyell McEwin Hospital (LMH) was undertaken over a five week study 
period in June and July 2013. The LMH is a tertiary level public teaching hospital with a 39 
bed WHU and is currently the second largest provider of obstetric services in South Australia 
(SA), accounting for 15.6% of hospital births in SA in 2010.12 The model of care provided at 
the LMH differs somewhat from other maternity units in SA. Women having a vaginal 
delivery give birth in the labour ward and if there are no complications with the mother or 
baby, they are discharged as soon as six hours after delivery. Midwives then undertake a 
series of home-visits to ensure that the mother and baby are doing well. Therefore the clinical 
case-mix of obstetric patients admitted to the WHU is mainly comprised of the more 
complicated vaginal deliveries in addition to caesarean deliveries and antenatal patients. 
Moreover, some uncomplicated vaginal deliveries are admitted to the WHU if the labour 
ward is over capacity or in the case that the neonate requires observation or treatment in the 
Special Care Nursery.  
 
During the study period the WHU was serviced by a ward-based clinical pharmacist during 
the hours of 9am to 1pm on Mondays to Fridays. As part of routine clinical care, the clinical 
pharmacist was responsible for undertaking a process of medication reconciliation for each 
obstetric/gynaecology patient admitted to the ward. Medication reconciliation is defined as 
the formal process of obtaining and verifying a complete and accurate list of a patient’s 
current medications, comparing the medications the patient has actually been prescribed to 
what they should be prescribed and discussing any discrepancies with the prescriber.21 In 
addition, medication chart reviews were undertaken for each patient on first contact with the 
pharmacy service and were repeated on subsequent days if time permitted. Any MRPs 
considered by the clinical pharmacist to require urgent action were brought to the attention of 




the Resident Medical Officer (RMO) on the ward immediately. Other less urgent issues were 
recorded, along with recommendations, on a separate report as they were identified and 
discussed with the RMO at the end of the clinical pharmacist’s shift. Patients in which 
medication reconciliation was not possible (i.e. interpreter unavailable, patient discharged 
prior to pharmacy review) were not included.  
  
All MRPs identified by the clinical pharmacist were recorded using a purpose built data 
collection instrument. Data were then entered into a spread sheet, including: type of patient 
(caesarean delivery, vaginal delivery, antenatal or gynaecology), the number of regular 
medications taken prior to admission and during hospital stay and length of hospital stay.  
The type of MRP was classified based on a modified version of the Hepler-Strand 
classification system. This system is based upon eight fundamental classes of MRPs and 
although first published some 23 years ago, is still widely used in studies internationally and 
serves to facilitate a greater understanding surrounding the circumstances in which various 
MRPs might develop.22 Medications involved in MRPs were classified according to the 
World Health Organisation Anatomical Therapeutic Chemical classification system. For 
simplicity, the clinical significance of each MRP was classified according to a modified 
version of the three level scale originally published by Cornish et al., which originally 
classified MRPs according to whether they had low, moderate, or severe potential to cause 
patient harm.23 We collapsed the three levels into two levels, with clinical significance 
classified either as being of low potential to result in patient deterioration or discomfort (level 
one) or of moderate or severe potential to result in patient deterioration or discomfort (level 
two). The clinical significance was initially assessed by the pharmacist recording the MRP 
and was subsequently discussed and reviewed by the remaining study authors, with 
consultation and review by a senior medical representative within the hospital. Inter-rater 




agreement was not evaluated between those assessing the clinical significance of each MRP. 
Medication-related discrepancies deemed not to be of clinical significance prior to 
commencing the study (i.e. the omission of pregnancy multi-vitamins in a patient who had 
taken them prior to admission) were not recorded as MRPs.  
 
Descriptive statistics were used to describe patient characteristics and the frequency and 
nature of identified MRPs. Non-parametric analyses were undertaken with multiple 
independent samples compared with a Kruskal-Wallis one-way analysis of variance 
(reporting adjusted significance using the Bonferroni correction) and two groups being 
compared with a Mann-Whitney-U Test. To compare categorical data, a Chi-Square Test was 
undertaken if values in each cell were more than or equal to five. In other cases a Fisher’s 
Exact Test was performed. Binary logistic regressions were used to calculate odds ratios 
(OR) with 95% confidence intervals for particular variables. Statistical analyses were 
undertaken using Statistical Package for the Social Sciences (SPSS, Chicago, IL) version 
22.0. Statistical significance was defined as a two-sided p-value of < 0.05. 
 
Results  
Data from a total of 241 patients was included in the study including 32 (13%) antenatal, 85 
(35%) caesarean delivery, 88 (37%) vaginal deliveries and 36 (15%) gynaecology patients. 
Of the 32 antenatal patients, 10 eventually proceeded to parturition during their hospital stay; 
seven had a caesarean section and three had a vaginal delivery. Significant differences were 
evidence across the four patient groups in relation to age, number of regular medications 
taken prior to and during admission, obesity and length of hospital stay (Table 1).  
 




A total of 454 discrete medication related problems were identified. The highest number of 
MRPs (221; 49%) were identified amongst women admitted following a caesarean delivery, 
with 83 of 85 women in this group experiencing at least one MRP (Table 1). Amongst 
postnatal women, those with a normal vaginal delivery were significantly less likely to 
experience a MRP than those with a caesarean delivery (OR 0.06, 95% CI 0.02-0.28). 
Additional factors associated with an increased likelihood of patient’s experiencing a MRP 
included increased age, length of hospital stay and number of regular medications taken prior 
to and during admission (Table 2). Within the obstetric cohort, advanced maternal age (>35 
years) was associated with a significantly increased likelihood of experiencing a MRP (OR 
7.75, 95% CI 1.30-infinity), whereas obesity (defined as Body Mass Index (BMI) > 30) was 
not (OR 1.71, 95% CI 0.75-3.90).  
 
The types of MRPs identified are presented in Table 3 which includes an example of each 
MRP category. When classified according to medication type, the most common therapeutic 
group implicated in MRPs was alimentary tract and metabolism, mainly aperients and 
vitamins (32%) (Figure 1). Medications for the nervous system, largely analgesics and 
antidepressants were also a large contributor to MRPs in the study, accounting for 30% of all 
MRPs.  A total of 39 (8.6%) of all MRPs were considered to be of moderate to high clinical 
significance (classified as level two MRPs). Despite being associated with the highest 
number of total MRPs, caesarean delivery was associated with the lowest proportion of level 
two MRPs, although this was not statistically significant (P=0.86; Table 1). A total of 136 
(30%) MRPs were identified in the process of completing medication reconciliation, whilst 
the remaining 318 (70%) were identified whilst undertaking daily medication chart reviews. 
A higher number of daily medication chart reviews was associated with the identification of 
at least MRP, as compared to no MRP (p=0.003). 





A total of 92 hours was spent on the ward by the clinical pharmacist over the five week 
period. The 241 patients in the study had a total length of stay of 941 days, with 0.44 level 
one MRPs and 0.041 level two MRPs identified per patient day.  
 
Discussion  
This study suggests that MRPs are prevalent in the area of women’s health, with an average 
of 0.482 MRPs identified per patient day, highlighting the importance of clinical pharmacy 
services in identifying, managing and preventing MRPs. With a paucity of existing data 
available on MRPs, the results of this study are important in highlighting the types of MRPs 
and medications likely to be involved in MRPs in this setting. While the majority of issues 
identified were of relatively modest clinical significance, the sheer frequency of some of 
these MRPs is suggestive of possible system problems inherent in day to day practices on the 
unit, potentially improved via simple systems changes.   
 
Few studies have investigated the nature and prevalence of MRPs occurring within a 
women’s health setting, with none undertaken in an Australian setting. A number of previous 
studies have focused on medication errors identified by error reporting systems or 
retrospective chart reviews.17-19  While such self-reported notifications are useful in providing 
potential insight into the nature of MRPs in this setting, they are likely to result in an 
underestimation of the total number of medication errors. Subsequent prospective studies also 
have their own limitations, such as focusing on medication errors associated with prescribed 
orders only, rather than the detailed range of MRPs explored in this present study.15, 16, 20 
Therefore, while the incidence of MRPs may appear approximately 10-fold higher in our 
present study compared with that reported previously (1.88 /woman vs. 0.20/woman16), this is 




likely to reflect methodological differences between studies. For example, the process of 
medication reconciliation as undertaken by the pharmacist proved crucial to the identification 
of many issues identified in our study. Previous research has reviewed the value of 
medication reconciliation in terms of reducing the incidence of both medication errors and 
subsequent ADRs.24 In the present study, medication reconciliation assisted in the 
identification of 136 MRPs (including six level two MRPs) over the five week period, 30% of 
the overall total. A further benefit of a detailed medication history is in identifying regular 
medications that have not been charted during hospital admission, this accounted for 112 
(28%) of MRPs identified in obstetric patients. Many of these involved the use of 
medications in the management of identified vitamin D deficiency (37%), asthma (35%) and 
depression (11%). It is important to be aware of a patient’s medical and medication history as 
these can have an impact on clinical care and the continued use of regular medications (e.g. 
antiepileptics) may be vital in ensuring adequate continued management of certain 
conditions. Furthermore, the charting of regular medications provides opportunities to discuss 
and support their use in the clinical setting (e.g. use of medications while breastfeeding). 
 
The identification of factors associated with an increased risk of experiencing a MRP are 
useful to determine what patients are at most risk of experiencing a MRP and therefore use 
this as a guide to prioritising work load on the ward. Factors associated with a significantly 
increased risk of experiencing a MRP included increased length of hospital stay, number of 
regular medications taken prior to and during admission, age and caesarean delivery. A 
number of these factors are likely to be closely correlated. For example, advancing age, 
which is more common amongst gynaecology patients than obstetric patients, is often 
associated with an increased occurrence of co-morbidities and subsequent medication use.  
 




In this study, within the obstetric setting, advanced maternal age (>35 years) was associated 
with a significantly increased likelihood of experiencing a MRP. This is probably not 
surprising given advanced maternal age has been associated with an increased risk of pre-
existing medical conditions (e.g. hypertension), obstetric complications (e.g. gestational 
diabetes) and adverse labour and birth outcomes (e.g. caesarean section).25 Like advanced 
maternal age, obesity also increases the risk of numerous pregnancy related complications.26  
However, despite obese women being more likely to have undergone caesarean section and 
be older compared to non-obese women, no difference was observed in relation to the 
presence of MRPs.  
 
Of note, while a number of risk factors were identified, the presence of a clinical significant 
level two MRP could not clearly be predicted based on any specific patient characteristic. 
This makes it difficult when prioritising clinical pharmacy service delivery, as only 
examining MRPs among patients considered to be at high risk could lead to missing clinical 
significant MRPs among other patients.  
 
In this study caesarean section patients experienced significantly more MRPs (p<0.001) and 
were significantly more likely to experience at least one MRP compared to those who had 
vaginal deliveries (OR 0.06, 95% CI 0.02-0.28), although they were not more likely to 
experience a level two MRP. In the South Australian public health system, patients are 
usually only eligible for an elective caesarean section if there is a medical reason (e.g. 
hypertension, antepartum haemorrhage or multiple pregnancy) for this to occur and 
emergency caesarean sections are performed for similar reasons in addition to foetal distress 
and failure to progress during labour.12 Further, a caesarean procedure is associated with 
increased maternal morbidity due to the invasive nature of the procedure, with complications 




including increased risk of thrombosis and post-partum haemorrhage.27  This increased 
complexity of caesarean section patients was evident in the present study in view of the 
significantly longer hospital stay, number of medications taken prior to admission and greater 
number of medications charted for caesarean patients as compared to those with vaginal 
deliveries. However, it should be noted that the vaginal delivery patient group in the present 
study are not necessarily representative of all vaginal births in the facility, and may in fact be 
skewed toward more medically complex cases, given the model of care implemented on the 
ward, which affects the ability to draw generalisations from these comparisons. This may 
help to explain the similar observed distribution of severity of MRPs amongst the vaginal and 
caesarean delivery patients. 
 
This study has a number of limitations. Firstly, MRPs were only assessed within the WHU, 
not the labour ward. Previous research suggests that these areas are not exempt from MRPs 
with one study reporting that half of errors reported in their study occurred here.18 Secondly, 
the generalisability of these results is influenced by the short study period and single-site 
methodology. While many aspects of clinical care remain constant (i.e. senior medical staff, 
nursing/midwifery staff), much of the ward based clinical care is undertaken by junior 
doctors on rotating placements, and therefore the presence of MRPs could differ according to 
their varying levels of experience in obstetrics and gynaecology. Furthermore, it is possible 
that the frequency and nature of MRPs identified within this setting may not be reflective of 
other hospitals due to differences in clinical staff, patient characteristics and/or differing 
clinical management protocols. Thirdly, the assignment of severity classifications to MRPs 
was not validated. While the severities were assigned by an experienced group of clinical 
pharmacists and reviewed by a senior medical representative within the hospital, inter-rater 
agreement was not evaluated. Finally, while the utility of a pharmacist in this setting is likely 




to extend beyond the identification and resolution of MRPs (e.g. the provision of information 
on the safety of medications in pregnancy and breastfeeding, as well as discharge 
counselling) these activities were not systematically recorded or analysed over the study 
period. Future research might reasonably include a more formal investigation into the overall 
value of a clinical pharmacist in this specialised context.  
 
In conclusion, this study demonstrates that MRPs are widespread within a women’s health 
setting. Future research should address whether clinical pharmacy services have the potential 
to reduce the frequency and significance of MRPs in this setting and whether this leads to 
improvements in patient health outcomes. 
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Table 1: Patient Characteristics and Number of MRPs by patient type 
Characteristic‡ Total Obstetrics Gynaecology Overall  
Comparison 



















median (range)  
1 (0-14) 2 (0-10)b 2 (0-9)a,b 1 (0-6)a 1.5 (0-14)a,b P=0.015 
Obese (BMI>30), 
n (%)^ 
86 (39%) 16 (53%)a 35 (41%)a,b 24 (28%)b 11 (55%)a P=0.021 
Length of stay 
(days), median 
(range) 





2 (0-13) 2 (0-12)a 3 (2-7)a 0 (0-6)b 2 (0-13)a P<0.001 




1 (1-9) 1 (1-9) a, b 2 (1-4) a 1 (1-3)b 1 (1-3) b P<0.001 
Number of MRPs 
identified, n 
454 74 221 105 54  
Median number 
of MRPs 
2 (0-14) 2 (0-14)a,b 3 (0-6)a 1 (0-5)b 1 (0-4)b P<0.001 






patients with ≥ 1 
MRP, n (%) 
201 
(83%) 
24 (75%)b 83 (98%)a 64 (73%)b 30 (83%)b P<0.001 




7 (9%) 11 (5%) 14 (13%) 7 (13%) P=0.864 
Abbreviations: MRP, medication related problem; BMI, body mass index;  
‡ Groups with different superscripts (e.g. a, b, c) are significantly different (p<0.05), while groups with the same 
superscript are not significantly different   
# Continuous variables were analysed with Kruskal-Wallis. Categorical variables were analysed with Chi-square 
tests or where the count in a cell was less than 5, by Fisher’s Exact test. 
^ Percentages are calculated from non-missing values (i.e.  nobese/nBMI recorded) 
* Number of regular medications charted as an inpatient was recorded at the point of initial review and updated 
if noted during a chart review that additional regular medicines were charted 
 
 





Table 2: Characteristics of Patients with ≥ 1 MRP compared to those who experienced no MRPs  
Characteristic No MRPs ≥ 1 MRP P Value # 
Number, n 40 201  
Age, median (range) 24.5 (18-69) 30 (17-83) P=0.002 
Length of stay, median (range) 3 (1-6) 4 (1-16) P=0.001 
Regular medications prior to admission, 
median (range) 
1 (0-5) 2 (0-14) P<0.001 
Regular medications as inpatient, 
median (range) ^ 
0 (0-6) 3 (0-13) P<0.001 
Obese (BMI>30), n (%) * 12 (32%) 74 (40%) P=0.462 
Abbreviations: MRP, Medication Related Problem; BMI, body mass index 
# Continuous variables were analysed with Mann-Whitney U Tests. Categorical variables were analysed with 
Chi-square tests or where the count in a cell was less than 5, by Fischer’s Exact test 
 ^ Number of regular medications charted as an inpatient was recorded at the point of initial review and updated if 
noted during a chart review that additional regular medicines were charted 











Table 3: Types of MRPs identified  
Type of MRP n (%) Example 
Incomplete medications charted on 
admission 
128 (28%) Patient’s asthma inhalers not charted for duration of 
stay. 
Dose too high 104 (23%) Patient’s receiving >4 g of paracetamol within 24 
hours post caesarean delivery. 
Incomplete drug order 75 (17%) Patient charted for fluticasone/salmeterol however no 
strength specified. Patient usually uses 250 
micrograms /50 micrograms. 
Additional medication required 55 (12%) Patient experienced significant blood loss in delivery 
and subsequently has a low haemoglobin (<10 g/dL), 
which is currently not being treated (require iron 
therapy).  
Therapeutic duplication 22 (5%) Patient is charted for paracetamol regularly and when 
required paracetamol/codeine, with no mention of 
maximum allowable dose in 24 hours. 
Incorrect medication choice 18 (4%) Patient has moderate to severe asthma and is 
prescribed labetalol for management of gestational 
hypertension. 
Drug-drug or drug-food interaction 10 (2%) Patient usually takes thyroxine on an empty stomach, 
however as an inpatient it has been prescribed and 
administered with breakfast.  
Dose too low 9 (2%) Patient received 20 mg daily of prophylactic 
enoxaparin post caesarean section. Guidelines 
recommend 40 mg. Patient weighed approximately 60 
kg.  
Failure to receive medication 9 (2%) Patient charted to receive levetiracetam dose post 
caesarean section, was not administered and thus 




patient went > 24 hours without receiving her anti-
epileptic medication. 
Unnecessary medication  8 (2%) Patient still charted for benzyl penicillin, for Group B 
Streptococci prophylaxis, in the postnatal period.  
Adverse drug reaction not documented 7 (2%) Patient had a prior reaction to iron polymaltose (rash 
and difficulty breathing), which was not documented 
on her chart during her admission for anaemia. 
Allergy to drug prescribed 6 (1%) Patient has a documented history of anaphylaxis to 
cephalosporins, and received one dose of cephazolin 
following caesarean delivery.  
Need for additional laboratory test 3 (1%) Patient underwent vaginal delivery, despite potentially 
active vaginal herpetic lesions. Neonate required IV 
antivirals and herpes swabs.  
Abbreviations: MRP, medication related problem 
 
 
Figure 1: Types of medication involved in medication related problems (MRP) according to Anatomical 
Therapeutic Chemical (ATC) classification 
 
 
 
